Metal Dyshomeostasis and Inflammation in Alzheimer’s and Parkinson’s Diseases: Possible Impact of Environmental Exposures
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
A dysregulated metal homeostasis is associated with both Alzheimer’s (AD) and Parkinson’s (PD) diseases; AD patients have decreased cortex and elevated serum copper levels along with extracellular amyloid-beta plaques containing copper, iron, and zinc. For AD, a putative hepcidin-mediated lowering of cortex copper mechanism is suggested. An age-related mild chronic inflammation and/or elevated intracellular iron can trigger hepcidin production followed by its binding to ferroportin which is the only neuronal iron exporter, thereby subjecting it to lysosomal degradation. Subsequently raised neuronal iron levels can induce translation of the ferroportin assisting and copper binding amyloid precursor protein (APP); constitutive APP transmembrane passage lowers the copper pool which is important for many enzymes. Using in silico gene expression analyses, we here show significantly decreased expression of copper-dependent enzymes in AD brain and metallothioneins were upregulated in both diseases. Although few AD exposure risk factors are known, AD-related tauopathies can result from cyanobacterial microcystin and β-methylamino-L-alanine (BMAA) intake. Several environmental exposures may represent risk factors for PD; for this disease neurodegeneration is likely to involve mitochondrial dysfunction, microglial activation, and neuroinflammation. Administration of metal chelators and anti-inflammatory agents could affect disease outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 3×
“Hepcidin restricts iron availability formicrobes by its binding to the only known cellular iron exporter ferroportin in host cell membranes which causes internalization and lysosomal ferroportin degradation (Figure 1) [19].”
BackgroundMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“Microglial cells comprise approximately 10–12% of the cells in the brain and dominate in the greymatter, with particularly high concentrations in the hippocampus, hypothalamus, basal ganglia, and SN [165–167].”
BackgroundProtein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Both underlying pathologies present different forms of protein aggregates that appear to be causally linked to their respective diseases [151].”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“α-Synuclein aggregation is thought to appear early in disease development and to spread across the nervous system as the disease progresses [121], and early neuroimmune activation by oligomerized αsynuclein has been speculated to precede neuronal degeneration.”
BackgroundCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“In particular, oxidative RNA damages, commonly observed in AD [10, 66, 67], may cause erroneous protein translations or truncations leading to dysfunctional proteins [66].”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 4×
“AD is a slowly progressing disease for which age is the most important risk factor [1, 2], and factors regulating metal homeostasis and inflammation known to change with age may be causally related to both AD and PD.”
BackgroundInfluentialA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“Unlike this genotype, a rare APP mutation positioned close to the site where β-secretase cleaves APP into amyloid-β leads to reduced formation of Aβ peptide monomers and protection against AD [27].”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“, TNFα, IL1β, and IL-6), and prostaglandins may be important mediators of dopaminergic cell death [170–172], which may propagate into a disease state [173].”
BackgroundLim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
Guralnik, J. M., Eisenstaedt, R. S., Ferrucci, L., Klein, H. G., & Woodman, R. C. (2004) · Blood · doi:10.1182/blood-2004-05-1812 · Cited by 1,450
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111 · cited 1×
“In the brain, microglia perform dynamic cellular functions that include synaptic plasticity [162], cleaning of cellular debris, wound healing through alternative activation [163, 164], and innate immune defence.”
BackgroundProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 1×
“Hindawi Publishing Corporation Oxidative Medicine and Cellular Longevity Volume 2013, Article ID 726954, 19 pages http://dx.doi.org/10.1155/2013/726954”
BackgroundInfluentialRitchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention
Kumar, A., & Loane, D. J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.008 · Cited by 710 · cited 1×
“Microglia activation is seen in multiple sclerosis [14], stroke [15], traumatic brain injury [16], Creutzfeldt-Jakob disease [17], in addition to PD and AD.”
BackgroundHepcidin and the iron-infection axis
Drakesmith, H., & Prentice, A. M. (2012) · Science · doi:10.1126/science.1224577 · Cited by 686
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Liang, W. S., Reiman, E. M., Valla, J., Dunckley, T., Beach, T. G., Grover, A., Niedzielko, T. L., Schneider, L. E., Mastroeni, D., Caselli, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709259105 · Cited by 585 · cited 3×
“(2007) [74] (GEO accession number GSE5281), which are comprehensive genome-wide gene expression studies of samples collected from six brain regions that are either histopathologically or metabolically relevant to AD: hippocampus (HIP), entorhinal cortex (EC), middle temporal gyrus (MTG), posterior cingulate cortex (PC…”
BackgroundMethodRogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551 · cited 17×
“Subsequently raised neuronal iron levels can induce translation of the ferroportin assisting and copper binding amyloid precursor protein (APP); constitutive APP transmembrane passage lowers the copper pool which is important for many enzymes.”
BackgroundInfluentialWine, Beer, Alcohol and Polyphenols on Cardiovascular Disease and Cancer
Arranz, S., Chiva-Blanch, G., Valderas-Martínez, P., Medina-Remón, A., Lamuela-Raventós, R. M., & Estruch, R. (2012) · Nutrients · doi:10.3390/nu4070759 · Cited by 534
Aqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion
Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., & Bush, A. I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23223 · Cited by 482
Mittelbronn, M., Dietz, K., Schluesener, H. J., & Meyermann, R. (2001) · Acta Neuropathologica · doi:10.1007/s004010000284 · Cited by 482
A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients
Maurer, I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00112-3 · Cited by 475
Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions
Loeffler, D. A., Connor, J. R., Juneau, P. L., Snyder, B. S., Kanaley, L., DeMaggio, A. J., Nguyen, H., Brickman, C. M., & LeWitt, P. A. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020710.x · Cited by 334
β-Amyloid Activates the O⨪2 Forming NADPH Oxidase in Microglia, Monocytes, and Neutrophils
Della Bianca, V., Dusi, S., Bianchini, E., Dal Prà, I., & Rossi, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.22.15493 · Cited by 324
Cevenini, E., Monti, D., & Franceschi, C. (2013) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32835ada13 · Cited by 317 · cited 1×
“In aging, amild systemic inflammation [37] and elevated iron levels in some organs (brain [38–40], skeletal muscle [41, 42], and liver [41]) is commonly seen, while iron levels decrease in bone marrow (related to anaemia) [43].”
BackgroundZou, K., Gong, J.-S., Yanagisawa, K., & Michikawa, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-12-04833.2002 · Cited by 305
Rotenone Model of Parkinson Disease
Panov, A., Dikalov, S., Shalbuyeva, N., Taylor, G., Sherer, T., & Greenamyre, J. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508628200 · Cited by 288
Neurological impacts from inhalation of pollutants and the nose–brain connection
Lucchini, R. G., Dorman, D. C., Elder, A., & Veronesi, B. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.001 · Cited by 283
Neuroprotective effect of natural products against Alzheimer’s disease
Essa, M. M., Vijayan, R. K., Castellano-Gonzalez, G., Memon, M. A., Braidy, N., & Guillemin, G. J. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0799-9 · Cited by 278
Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier
Wu, L. J.-C., Leenders, A. G. M., Cooperman, S., Meyron-Holtz, E., Smith, S., Land, W., Tsai, R. Y. L., Berger, U. V., Sheng, Z.-H., & Rouault, T. A. (2004) · Brain Research · doi:10.1016/j.brainres.2003.10.066 · Cited by 210
Moderate alcohol consumption and cognitive risk
Neafsey, E., & Collins, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s23159 · Cited by 205
Moon, M., Kim, H. G., Hwang, L., Seo, J.-H., Kim, S., Hwang, S., Kim, S., Lee, D., Chung, H., Oh, M. S., et al. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9037-x · Cited by 203 · cited 1×
“Levels of proinflammatory cytokines are elevated in PD patients compared with healthy subjects, and it has been shown that these cytokines can contribute to dopaminergic cell death in vivo [132, 133].”
BackgroundBesson-Fournier, C., Latour, C., Kautz, L., Bertrand, J., Ganz, T., Roth, M.-P., & Coppin, H. (2012) · Blood · doi:10.1182/blood-2012-02-411470 · Cited by 179
Dysregulated neuronal–microglial cross-talk during aging, stress and inflammation
Jurgens, H. A., & Johnson, R. W. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2010.11.014 · Cited by 179
A role for microglia in synaptic plasticity?
Tremblay, M.-È., & Majewska, A. K. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.4.2.14506 · Cited by 176 · cited 1×
“In the brain, microglia perform dynamic cellular functions that include synaptic plasticity [162], cleaning of cellular debris, wound healing through alternative activation [163, 164], and innate immune defence.”
BackgroundBoll, M.-C., Alcaraz-Zubeldia, M., Montes, S., & Rios, C. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9610-3 · Cited by 173
Use of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173
RNA oxidation in Alzheimer disease and related neurodegenerative disorders
Nunomura, A., Hofer, T., Moreira, P. I., Castellani, R. J., Smith, M. A., & Perry, G. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0508-1 · Cited by 148
Self-citationCollingwood, J. F., Chong, R. K. K., Kasama, T., Cervera-Gontard, L., Dunin-Borkowski, R. E., Perry, G., Pósfai, M., Siedlak, S. L., Simpson, E. T., Smith, M. A., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14211 · Cited by 147
Sankarapandi, S., Zweier, J. L., Mukherjee, G., Quinn, M. T., & Huso, D. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0658 · Cited by 136
Park, K. W., Baik, H. H., & Jin, B. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803392 · Cited by 84 · cited 2×
“cytokines, such as TNFα, IL-1β [177], IL-4 [178] and IL-13 [179], are reported to initiate microglial NADPH oxidase activation and O 2 ∙− generation.”
BackgroundIron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys
Cass, W. A., Grondin, R., Andersen, A. H., Zhang, Z., Hardy, P. A., Hussey-Andersen, L. K., Rayens, W. S., Gerhardt, G. A., & Gash, D. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.010 · Cited by 67
Petri, S., Calingasan, N. Y., Alsaied, O. A., Wille, E., Kiaei, M., Friedman, J. E., Baranova, O., Chavez, J. C., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04604.x · Cited by 55 · cited 1×
“Other chelators tested in AD models having showed positive effects include the iron chelatorM30 [92], the copper chelators JKL-169 [102] and IQM-622 [103], and the calcium/copper/zinc chelators DP-109 andDP-460 [104, 105].”
Background
Cited by
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
“(SOD1) and antioxidant protein 1 (ATOX1), was markedly reduced in multiple microarray studies of AD patients, reinforcing the lack of copper [84].”
BackgroundCopper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
Gromadzka, G., Tarnacka, B., Flaga, A., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239259 · Cited by 339
Neurodegenerative and neurological disorders by small inhaled particles
Heusinkveld, H. J., Wahle, T., Campbell, A., Westerink, R. H. S., Tran, L., Johnston, H., Stone, V., Cassee, F. R., & Schins, R. P. F. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.07.007 · Cited by 331
Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications
Liu, J.-L., Fan, Y.-G., Yang, Z.-S., Wang, Z.-Y., & Guo, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00632 · Cited by 284
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
Metadata
- Authors
- Myhre, O., Utkilen, H., Duale, N., Brunborg, G., & Hofer, T.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-19
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W1992178895
- Cited by
- 152
- References
- 54
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.